This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs
by Zacks Equity Research
ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.
CVS Health (CVS) Invests in Renewable Energy With New Pact
by Zacks Equity Research
CVS Health (CVS) to receive clean, renewable energy through a 12-year agreement with Constellation.
Charles River's (CRL) Improved Volume Aids Amid Margin Woe
by Zacks Equity Research
Charles River (CRL) registers growth in small research models, research model services and the Cell Solutions business.
Charles River (CRL) Introduces LVV Packaging Plasmids
by Zacks Equity Research
Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.
Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe
by Zacks Equity Research
Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
by Zacks Equity Research
Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.
Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform
by Zacks Equity Research
Myriad Genetics (MYGN) announces research collaboration with MD Anderson on metastatic RCC with its high-definition MRD research testing platform based on whole-genome sequencing.
Inspire (INSP) Gets FDA Nod for Expanded Indication of AHI
by Zacks Equity Research
The FDA approves Inspire's (INSP) application to expand the indication to include patients with AHI up to 100 events per hour.
VREX vs. HAE: Which Stock Is the Better Value Option?
by Zacks Equity Research
VREX vs. HAE: Which Stock Is the Better Value Option?
Earnings Estimates Moving Higher for Haemonetics (HAE): Time to Buy?
by Zacks Equity Research
Haemonetics (HAE) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes
by Zacks Equity Research
Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.
Neogen (NEOG) Introduces 2 Assays for Histamine Detection
by Zacks Equity Research
Neogen (NEOG) launches Reveal for Histamine and Reveal Q+ for Histamine assays for the detection of Histamine.
Haemonetics (HAE) Hospital Arm Grows, Plasma Volume Improves
by Zacks Equity Research
Within Haemonetics (HAE) Vascular Closure, growth is led by the opening of new accounts and increasing penetration to gain share in the top U.S. EP hospitals.
Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
by Zacks Equity Research
Here is how Alimera Sciences (ALIM) and Haemonetics (HAE) have performed compared to their sector so far this year.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
How Much Upside is Left in Haemonetics (HAE)? Wall Street Analysts Think 27.09%
by Zacks Equity Research
The mean of analysts' price targets for Haemonetics (HAE) points to a 27.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Buy Stocks for May 26th
by Zacks Equity Research
HDELY, WIRE, HAE, GWW and MUSA have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2023.
HAE or PODD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. PODD: Which Stock Is the Better Value Option?
Is Apyx Medical (APYX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Apyx Medical (APYX) and Haemonetics (HAE) have performed compared to their sector so far this year.
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 13.24% and 6.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Verano Holdings Corp. (VRNOF) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 57.14% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
VREX or HAE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
VREX vs. HAE: Which Stock Is the Better Value Option?